KR20240019218A - T 세포 관여자 분자 및 이의 용도 - Google Patents

T 세포 관여자 분자 및 이의 용도 Download PDF

Info

Publication number
KR20240019218A
KR20240019218A KR1020247000080A KR20247000080A KR20240019218A KR 20240019218 A KR20240019218 A KR 20240019218A KR 1020247000080 A KR1020247000080 A KR 1020247000080A KR 20247000080 A KR20247000080 A KR 20247000080A KR 20240019218 A KR20240019218 A KR 20240019218A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
tce
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000080A
Other languages
English (en)
Korean (ko)
Inventor
요하네스 브로지
크리스토프 달호프
토비아스 라움
조첸 에스. 펜지알렉
리사 윈클
마르쿠스 무엔즈
나단 윌리엄 피어스
아그니에츠카 키엘체프스카
웬타오 첸
다렌 엘. 베이츠
클라우디아 블뤼멜
조나스 칼-조세프 호너
Original Assignee
암젠 리서치 (뮌헨) 게엠베하
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 리서치 (뮌헨) 게엠베하, 암젠 인크 filed Critical 암젠 리서치 (뮌헨) 게엠베하
Publication of KR20240019218A publication Critical patent/KR20240019218A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020247000080A 2021-06-04 2022-06-02 T 세포 관여자 분자 및 이의 용도 Pending KR20240019218A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163197265P 2021-06-04 2021-06-04
US63/197,265 2021-06-04
US202163236547P 2021-08-24 2021-08-24
US63/236,547 2021-08-24
PCT/US2022/032006 WO2022256559A1 (en) 2021-06-04 2022-06-02 T cell engager molecules and uses thereof

Publications (1)

Publication Number Publication Date
KR20240019218A true KR20240019218A (ko) 2024-02-14

Family

ID=82258382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000080A Pending KR20240019218A (ko) 2021-06-04 2022-06-02 T 세포 관여자 분자 및 이의 용도

Country Status (9)

Country Link
US (1) US20250129160A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347654A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520666A (cg-RX-API-DMAC7.html)
KR (1) KR20240019218A (cg-RX-API-DMAC7.html)
AU (1) AU2022287014A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221250A1 (cg-RX-API-DMAC7.html)
IL (1) IL308809A (cg-RX-API-DMAC7.html)
MX (1) MX2023014415A (cg-RX-API-DMAC7.html)
WO (1) WO2022256559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022285741A1 (en) * 2021-06-04 2023-12-14 Amgen Inc. Anti-ccr8 antibodies and uses thereof
PE20240638A1 (es) 2021-07-14 2024-03-27 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
PE20252286A1 (es) * 2023-01-18 2025-09-18 Genentech Inc Anticuerpos multiespecificos y usos de estos
WO2024248037A1 (ja) * 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
CN122374018A (zh) * 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
WO2025259749A1 (en) * 2024-06-12 2025-12-18 Amgen Inc. Stable single-chain variable fragments
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2026019990A1 (en) * 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies
WO2026072755A2 (en) * 2024-09-26 2026-04-02 Amgen Inc. Single-chain fab proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP3218413A4 (en) * 2014-11-12 2018-03-28 Memorial Sloan-Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
UA126657C2 (uk) * 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
AR107582A1 (es) * 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
JP7231158B2 (ja) * 2016-10-19 2023-03-01 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Cd133結合剤およびその使用
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit

Also Published As

Publication number Publication date
JP2024520666A (ja) 2024-05-24
IL308809A (en) 2024-01-01
EP4347654A1 (en) 2024-04-10
MX2023014415A (es) 2024-02-08
WO2022256559A1 (en) 2022-12-08
AU2022287014A9 (en) 2023-12-14
US20250129160A1 (en) 2025-04-24
CA3221250A1 (en) 2022-12-08
AU2022287014A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
AU2022201144B2 (en) Antigen binding molecules comprising a TNF family ligand trimer
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR102473028B1 (ko) 항-tim-3 항체 및 조성물
KR102737715B1 (ko) Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
CN107922496B (zh) IL2Rβ/通用γ链抗体
CN108137687B (zh) 抗ox40抗体及其用途
KR102713355B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN113423733A (zh) 结合tslp的抗体及其用途
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
KR102763369B1 (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
CN108659112B (zh) 一种非对称双特异性抗体
KR102920224B1 (ko) 인간화 항-VEGF Fab 항체 단편 및 이의 용도
US20250129160A1 (en) T cell engager molecules and uses thereof
KR20220147642A (ko) Il4r에 결합하는 항체 및 이의 용도
KR20200044899A (ko) 암의 치료 및 진단을 위한 tim-3 길항제
KR20120130767A (ko) 항체
CN115348970A (zh) 结合siglec15的抗体及其用途
KR102920217B1 (ko) 인간화 항-vegf 단클론 항체
KR20220108747A (ko) 신규한 결합 분자 및 이의 용도
CN115297888A (zh) 结合cd40的抗体及其用途
TW202313110A (zh) 癌症之治療
JP2024519078A (ja) 抗cea抗体及びその使用方法
KR102934248B1 (ko) Il6r에 결합하는 항체 및 이의 용도
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250530

Comment text: Request for Examination of Application